

# Maria Sandovici

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4698025/publications.pdf>

Version: 2024-02-01

36  
papers

804  
citations

623734

14  
h-index

580821

25  
g-index

36  
all docs

36  
docs citations

36  
times ranked

586  
citing authors

#	ARTICLE	IF	CITATIONS
1	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, e1-e23.	1.9	128
2	Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis. <i>JAMA Internal Medicine</i> , 2020, 180, 1295.	5.1	76
3	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020, 59, 487-494.	1.9	56
4	Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?. <i>Arthritis and Rheumatology</i> , 2018, 70, 1366-1376.	5.6	54
5	Massive B-Cell Infiltration and Organization Into Artery Tertiary Lymphoid Organs in the Aorta of Large Vessel Giant Cell Arteritis. <i>Frontiers in Immunology</i> , 2019, 10, 83.	4.8	45
6	Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis. <i>Rheumatology</i> , 2019, 58, 1383-1392.	1.9	43
7	Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica. <i>Frontiers in Immunology</i> , 2019, 10, 1981.	4.8	40
8	Visual and semiquantitative assessment of cranial artery inflammation with FDG-PET/CT in giant cell arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 616-623.	3.4	40
9	Distinct macrophage phenotypes skewed by local granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) are associated with tissue destruction and intimal hyperplasia in giant cell arteritis. <i>Clinical and Translational Immunology</i> , 2020, 9, e1164.	3.8	39
10	Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica. <i>Rheumatology</i> , 2022, 61, 1072-1082.	1.9	29
11	A Distinct Macrophage Subset Mediating Tissue Destruction and Neovascularization in Giant Cell Arteritis: Implication of the YKL40/Interleukin-13 Receptor 1±2 Axis. <i>Arthritis and Rheumatology</i> , 2021, 73, 2327-2337.	5.6	27
12	Towards precision medicine in ANCA-associated vasculitis. <i>Rheumatology</i> , 2018, 57, 1332-1339.	1.9	23
13	Gene therapy with adenovirus-delivered indoleamine 2,3-dioxygenase improves renal function and morphology following allogeneic kidney transplantation in rat. <i>Journal of Gene Medicine</i> , 2011, 13, 373-381.	2.8	21
14	Association of the CXCL9-CXCR3 and CXCL13-CXCR5 axes with B-cell trafficking in giant cell arteritis and polymyalgia rheumatica. <i>Journal of Autoimmunity</i> , 2021, 123, 102684.	6.5	20
15	Adenovirus-mediated interleukin-13 gene therapy attenuates acute kidney allograft injury. <i>Journal of Gene Medicine</i> , 2007, 9, 1024-1032.	2.8	17
16	Functionally Heterogenous Macrophage Subsets in the Pathogenesis of Giant Cell Arteritis: Novel Targets for Disease Monitoring and Treatment. <i>Journal of Clinical Medicine</i> , 2021, 10, 4958.	2.4	15
17	High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica. <i>Rheumatology</i> , 2020, 59, 176-184.	1.9	13
18	Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e210-e210.	0.9	13

#	ARTICLE	IF	CITATIONS
19	Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	13
20	Immune modulation and graft protection by gene therapy in kidney transplantation. <i>European Journal of Pharmacology</i> , 2008, 585, 261-269.	3.5	11
21	Artery tertiary lymphoid organs in giant cell arteritis are not exclusively located in the media of temporal arteries. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e16-e16.	0.9	11
22	Towards graft-specific immune suppression: Gene therapy of the transplanted kidney. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 1358-1368.	13.7	10
23	Management of immune checkpoint inhibitor-induced polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e263-e263.	0.9	10
24	Methotrexate in Giant Cell Arteritis Deserves a Second Chance – A High-dose Methotrexate Trial Is Needed. <i>Journal of Rheumatology</i> , 2019, 46, 453-454.	2.0	8
25	Angiotensin-2/1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica. <i>Arthritis Research and Therapy</i> , 2022, 24, 65.	3.5	8
26	Phenotypic, transcriptomic and functional profiling reveal reduced activation thresholds of CD8+ T cells in giant cell arteritis. <i>Rheumatology</i> , 2022, 62, 417-427.	1.9	8
27	Aortic involvement in giant cell arteritis. <i>Joint Bone Spine</i> , 2021, 88, 105045.	1.6	6
28	CD8+ T Cells in GCA and GPA: Bystanders or Active Contributors?. <i>Frontiers in Immunology</i> , 2021, 12, 654109.	4.8	6
29	Need and value of targeted immunosuppressive therapy in giant cell arteritis. <i>RMD Open</i> , 2022, 8, e001652.	3.8	6
30	The protective effect of 1-methyltryptophan isomers in renal ischemia-reperfusion injury is not exclusively dependent on indolamine 2,3-dioxygenase inhibition. <i>Biomedicine and Pharmacotherapy</i> , 2021, 135, 111180.	5.6	5
31	OP0211 – ULTRASONOGRAPHY CAN POTENTIALLY BE THE FIRST CHOICE OF IMAGING IN SUSPECTED EXTRA-CRANIAL GCA. , 2019, , .		2
32	Encouraging data on rituximab in polymyalgia rheumatica. <i>Lancet Rheumatology</i> , The, 2021, , .	3.9	1
33	303 – LEUKOCYTE DYNAMICS BEFORE, DURING AND AFTER TREATMENT IN GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATIC PATIENTS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
34	055 – HIGH SERUM ANGIOPOIETIN-2 LEVELS IDENTIFY LARGE VESSEL INFLAMMATION IN PATIENTS WITH POLYMYALGIA RHEUMATICA. <i>Rheumatology</i> , 2019, 58, .	1.9	0
35	FRI0275 – HIGH ANGIOPOIETIN-2 LEVELS ASSOCIATE WITH ARTERIAL INFLAMMATION AND LONG-TERM GLUCOCORTICOID REQUIREMENT IN POLYMYALGIA RHEUMATICA. , 2019, , .		0
36	SAT0228 – LEUKOCYTE DYNAMICS IN GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA PATIENTS BEFORE, DURING AND AFTER TREATMENT. , 2019, , .		0